BriaCell Therapeutics Corp.
BCTXLHealthcare|Biotechnology|CA
$0.97
+0.17 (+20.37%)
Tangible Book / Share
$1.77
Cash / Share
$2.36
About
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Stock Price
+3.0%(1Y)
1M
-12.2%
3M
+3.0%
6M
+3.0%
YTD
+3.0%
1Y
+3.0%
3Y
+3.0%
5Y
+3.0%
Pipeline Summary
4 total trials3
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 1Completed: 2Unknown: 1
Active Trials (1)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer
Phase 3Recruiting
Enrollment: 404 participants
Key Facts
Market Cap$8.5M
Employees31
CEOWilliam V. Williams
IPO DateJan 14, 2026
Beta-0.17
52-Week Range$0.7 – $1.23
Avg Volume15,828
ExchangeNASDAQ
Websitebriacell.com
Ownership
Shares Outstanding8.7M
Data last updated: Nov 9, 2026, 03:58 AM